The Canadian company Organigram will sell 6.5 tons of cannabis to Israel

A 7 year cannabis partnership between Israel and the Canadian company, Organigram was just established. Organigram will secure Israel up to 6 tons of cannabis with a possibility of more, which will benefit the cannabis business in the country. Organigram is considered as one of the leading companies worldwide, being worth around $469 million on the Canadian stock market.

Kanduk Israel signed a comprehensive cooperation agreement with the Canadian company Organigram, which focuses on indoor cannabis growing facilities and is considered one of the leading companies worldwide in this field.

Organigram, which today trades on the Canadian stock exchange worth $469 million, will market to Israel, under this new agreement, up to 6 tons of cannabis from its medical cannabis brand Organicare.

If you want to know more about cannabis, how Canada is expanding its cannabis international relationships and securing its businesses in Israel, and to find out the latest hemp news, download the Hemp.im mobile application.

Israel and Canada’s cannabis partnership

Kanduk reported this morning that, in the first phase, 1 ton of cannabis will arrive in the next few weeks, and is expected to be the largest Indore stock in Israel, and possibly the first, depending on the final arrival date.

An additional 2 tons are expected to arrive within a year and a half, with the option to order an additional 3 tons thereafter. The agreement is for 7.5 years, which will seal Israel and Canada’s cannabis partnership. According to Kanduk, Organigram’s growing facility is the “largest and most advanced in the world” and that hundreds of millions of dollars have been invested in it.

Kanduk has not revealed which varieties of Organism’s variety are to arrive in Israel, but it is likely that these cannabis species have about 18% of THC that can enter the T20 / C4 category, which is considered the most popular.

The varieties will be marketed under a local brand of ‘Kanduk’ and not in the original packaging, but the two companies agreed to discuss the possibility of marketing the Canadian company’s products under a new joint brand in Israel.

The significant advantage of ‘Indore’ growth compared to greenhouse growth is the relative cleanliness of pests and the flats resulting from constant and accurate temperature, humidity and lighting conditions – which may exempt the produce from screening for mold spores and fungal toxins.

At present, there are no Indore products in Israel, but there are two local companies in the final stages of production and marketing. Beneath the surface, there is a silent competition for the title of “The First Legal Indoor Products in Israel”.

Canada is expanding into other cannabis markets and is building up international relationships

Canada already markets a wide range of cannabis varieties made by an international Canadian company, “Tilleyri”, but these varieties are produced in greenhouses at the company’s facility in Portugal. “Organigram” will be the third Canadian company to market Canadian-made cannabis in Israel after the companies “Supreme” and “Hexo”.

At the beginning of the year (2020), Organigram signed a distribution agreement with Canada’s largest pharmacy chain, Shoppers, and is considered one of the top 10 cannabis companies in the country.

Organigram CEO Greg Engel said: “Success in international cannabis markets requires careful assessment of opportunities and identifying strong partners at the highest level. For this reason, we are proud to work with Kanduk, a company we believe is focused on high quality manufacturing and a commitment to helping patients.”

Kanduk Chairman Ehud Barak said: “In our mission to fulfill patients’ needs and improve their quality of life, we are happy and proud to work with Organigram to improve the health of patients in Israel as well as other countries that recognize the benefits of this treatment for people who need it.”

__

(Featured image by Free-Photos via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Hemp.im, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in קנאביס, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.